Antiviral therapy in patients with anogenital herpesvirus infection
Objective. To systematize the results of investigating the clinical efficiency and safety of etiotropic antiviral therapy in patients with the different course of genital herpes.Rakhmatulina M.R.
Material and methods. Foreign and Russian articles published on the investigation topic were analyzed. The search depth was 20 years.
Results. The paper gives data on the efficiency of episodic and suppressive therapy in patients with anogenital herpes infection.
Conclusion. The use of the antiviral drug valacyclovir in the therapy of genital herpes contributes to the reduction of the clinical severity and rates of recurrences, lowers the risk of potential transmission of herpes simplex virus, including asymptomatic virus shedding, and substantially improves quality of life in the patients.
Keywords
herpes simplex virus
genital herpes
episodic therapy
suppressive therapy
valacyclovir
References
1. Global strategy for the prevention and control of sexually transmitted infections: 2006-2015: breaking the chain of transmission. http://www.who.int/mediacentre/factsheets/fs400/ru/
2. Rakhmatulina M.R. Current possibilities in therapy for sexually transmitted viral infections. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2015; 7: 100-5. (in Russian)
3. Belousova T.A., Goryachkin M.V. Etiotropic therapy of herpes simplex: focus on valacyclovir. Russian Medical Journal. 2015; 9: 520. (in Russian)
4. Beauman J.G. Genital herpes: a review. Am. Fam. Physician. 2005; 72: 1527-34.
5. Federal clinical guidelines. Dermatovenerology 2015. Moscow: DEKS-PRESS; 2016. 768p. (in Russian)
6. Perlamutrov Yu.N., Chernova N.I. The effectiveness of valaciclovir in the therapy of orofascial herpes. Russian Medical Journal. 2013; 22: 1084-8. (in Russian)
7. Khaldin A.A., Gilyadov A.D., Byhanova O.N., Isaeva D.R. Reproduced acyclic synthetic nucleosides in etiotropic therapy for recurrences of herpes simplex. Klinicheskaya dermatologiya i venerologiya. 2014; 2: 79-83. (in Russian)
8. Bodsworth N.J., Crooks R.J., Borelli S. et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. Genitourin. Med. 1997; 73: 110–6.
9. Strand A., Patel R., Wulf H.C. et al. Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir. Sex. Transm. Infect. 2002; 78: 435-9.
10. Patel R., Bodsworth N.J., Woolley P. et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourin. Med. 1997; 73: 105-9.
11. Romanowski B., Marina R.B., Roberts J.N. Patients’ preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex. Transm. Dis. 2003; 30: 226–31.
12. Brentjens M.H., Yeung-Yue K.A., Lee P.C. et al. Recurrent genital herpes treatments and their impact on quality of life. Pharmacoeconomics. 2003; 21: 853–63.
13. Corey L., Wald A., Patel R. et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. 2004: 350: 11-20.
Received 21.04.2017
Accepted 28.04.2017
About the Authors
Rakhmatulina Margarita Rafikovna, MD, Professor of the Department of Dermatovenereology and Cosmetology with the Course of Clinical Laboratory Diagnostics,A.I. Burnazyan Federal Medical Biophysical Center, Federal Biomedical Agency of Russia. 123098, Russia, Moscow, Zhivopisnaya str. 46. Tel.: +79162031003.
E-mail: ra.marg@yandex.ru
For citations: Rakhmatulina M.R. Antiviral therapy in patients with anogenital herpesvirus infection. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (6): 165-9. (in Russian)
http://dx.doi.org/10.18565/aig.2017.6.165-9
Similar Articles
